Information Provided By:
Fly News Breaks for March 16, 2018
SRPT
Mar 16, 2018 | 08:00 EDT
SunTrust analyst Edward Nash raised his price target on Sarepta to $95 after the company's announcement pursuing accelerated golodirsen approval for certain patients with Duchenne Muscular Dystrophy. The analyst adds that based on the uptake and growth of eteplirsen, a similar trajectory can be assumed for golodirsen leading to an approval in 2019. Nash keeps his Buy rating on Sarepta.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.